Business Wire

SISVEL-GROUP

7.5.2020 10:49:05 CEST | Business Wire | Press release

Share
A Final Victory for Sisvel Before the German Federal Supreme Court (BGH) In the Sisvel vs. Haier Case

On May 5 the German Federal Supreme Court heard the arguments in the case between Sisvel and Haier regarding Sisvel’s request for injunctive relief for infringement of cellular standard essential patents (SEPs) owned by Sisvel. The decision rendered on May 5, marks the final decision on the infringement of Sisvel’s European patent EP 0 852 885 (“EP 885”), and the related FRAND defense after a 6 year long legal dispute.

Prior to this verdict, on March 10, 2020 the BGH had already given final confirmation that Sisvel’s EP 885 should be considered valid. The nullity actions had been filed by Haier and ZTE. On April 28, 2020 there was a subsequent decision by the BGH confirming the validity of Sisvel’s European patent EP 1 264 504, where Haier and ZTE were likewise the plaintiffs. Last but not least, yesterday the BGH ruled that in the infringement proceedings of EP 885 the decision of the Appeal Court in Düsseldorf from March 2017 is reversed in relation to the finding on costs and insofar as the decision has found to the detriment of the plaintiff, i.e. Sisvel.

“Sisvel welcomes the results we have obtained in the recent weeks before the highest court for patent matters in Germany. Whilst we still see a too much hold-out and “efficient infringement” strategies being used, we have every confidence that Haier and implementers alike will take notice of this landmark decision.” said Florian Cordes, who managed the litigation for Sisvel, “We also trust that the decision of the BGH will provide certain instructions to the market and courts how implementers of SEPs should behave, which may prevent future disputes.”

The patents asserted against Haier are part of Sisvel’s bilateral “Wireless” program and are available under license with its “Mobile Communication Program” (MCP) as well. The Sisvel MCP is a licensing platform that licenses cellular (2G, 3G, 4G) standard essential patents, which are owned by a variety of companies, including Airbus DS, KPN, Mitsubishi Electric, Orange, Sisvel and 3G Licensing.

For additional information about the program, please visit the dedicated section of our website: https://www.sisvel.com/licensing-programs/wireless-communications/mcp/introduction

About Sisvel

Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.

For additional information, please visit: www.sisvel.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release

Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release

Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be

From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release

Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and

Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 14:30:00 CEST | Press release

Public equities have re-emerged as the primary destination for incremental capital Private markets remain a strategic pillar of family office portfolios Artificial intelligence is moving from experimentation toward implementation Cross-border complexity is rising as families become increasingly international Leadership succession and next-generation preparedness are now immediate priorities rather than distant considerations Watch Citi Wealth’s Global Family Office leadership discuss the report’s findings here. Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Tod

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 14:30:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye